Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D01479)
Name
Tetracaine
Synonyms    Click to Show/Hide the Synonyms of This API
tetracaine; 94-24-6; Amethocaine; Pontocaine; 2-(Dimethylamino)ethyl 4-(butylamino)benzoate; Dicaine; Laudocaine; Metraspray; Tetrakain; Anetain; Contralgin; Meethobalm; Mucaesthin; Tetracaina; Tetracainum; Uromucaesthin; Fissucain; Intercain; Medicaine; Niphanoid; Rexocaine; Dicain; Dikain; Medihaler-Tetracaine; 2-(Dimethylamino)ethyl p-(butylamino)benzoate; p-Butylaminobenzoyl-2-dimethylaminoethanol; Benzoic acid, 4-(butylamino)-, 2-(dimethylamino)ethyl ester; Diaethylaminoaethanol ester der p-butylaminobenzoesaeure; 4-(Butylamino)benzoic acid 2-(dimethylamino)ethyl ester; Dimethylaminoethyl p-butyl-aminobenzoate; UNII-0619F35CGV; CHEBI:9468; p-(Butylamino)benzoic acid, 2-(dimethylamino)ethyl ester; MFCD00053787; CHEMBL698; BENZOIC ACID, p-(BUTYLAMINO)-, 2-(DIMETHYLAMINO)ETHYL ESTER; 2-Dimethylaminoethylester kyseliny p-butylaminobenzoove; 0619F35CGV; Butylocaine; Tetracaine, 98%; Tetrakain [Czech]; Tetracaine Base; Tetracainum [INN-Latin]; Tetracaina [INN-Spanish]; p-(butylamino)benzoic acid beta-(dimethylamino)ethyl ester; Amethocaine (TN); Tetracaine (USP/INN); NCGC00016049-02; CAS-136-47-0; EINECS 202-316-6; BRN 2216051; Landocaine; Tetracaine [USP:INN:BAN]; Amethocaine HCl; 2-Dimethylaminoethylester kyseliny p-butylaminobenzoove [Czech]; Diaethylaminoaethanol ester der p-butylaminobenzoesaeure [German]; TE4; Spectrum_001032; Pantocaine (Salt/Mix); 100311-22-6; Prestwick0_000571; Prestwick1_000571; Prestwick2_000571; Prestwick3_000571; Spectrum2_001328; Spectrum3_000562; Spectrum4_000351; Spectrum5_001072; Lopac-T-7508; Epitope ID:174843; Lopac0_001211; SCHEMBL34714; BSPBio_000382; BSPBio_001944; KBioGR_000781; KBioSS_001512; 4-14-00-01172 (Beilstein Handbook Reference); DivK1c_000607; SPBio_001455; SPBio_002601; BPBio1_000422; Tetracaine, >=98% (TLC); DTXSID1043883; KBio1_000607; KBio2_001512; KBio2_004080; KBio2_006648; KBio3_001444; NINDS_000607; BCPP000048; ACT04765; ALBB-025902; BCP04777; HY-A0079; ZINC1530811; BDBM50017659; KM3267; SBB058194; STL483844; AKOS015889234; AC-3480; CCG-205285; DB09085; MCULE-8973928579; SDCCGSBI-0051178.P005; IDI1_000607; NCGC00016049-01; NCGC00016049-03; NCGC00016049-04; NCGC00016049-14; NCGC00162367-01; K715; ST099115; SY066710; BCP0726000001; SBI-0051178.P004; AB00053549; FT-0656378; Tetracaine, meets USP testing specifications; .beta.-Dimethylaminoethyl p-butylaminobenzoate; 2-(Dimethylamino)ethyl4-(n-butylamino)benzoate; C07526; D00551; 2-(Dimethylamino)ethyl 4-(butylamino)benzoate #; AB00053549-11; AB00053549_12; AB00053549_13; Q419608; Q-201805; BRD-K45071273-003-05-8; BRD-K45071273-003-15-7; Tetracaine, United States Pharmacopeia (USP) Reference Standard; benzoic acid, 4-(butylamino)-, 2-(dimethylamino)ethyl ester ,hydrochloride; BENZOIC ACID,4-BUTYLAMINO,2-DIMETHYLAMINOETHYL ESTER PANTOCAIN BASE
Clinical Status
Approved
PubChem CID
5411
Formula
C15H24N2O2
Canonical SMILES
CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C
InChI
1S/C15H24N2O2/c1-4-5-10-16-14-8-6-13(7-9-14)15(18)19-12-11-17(2)3/h6-9,16H,4-5,10-12H2,1-3H3
InChIKey
GKCBAIGFKIBETG-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=5411"></iframe>
3D MOL is unavailable 2D MOL
Physicochemical Properties Molecular Weight 264.36 Topological Polar Surface Area 41.6
XlogP 3.7 Complexity 249
Heavy Atom Count 19 Rotatable Bond Count 9
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 4
Full List of Drug Formulations (DFMs) Containing This API
          Tetracaine 1% cream Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Water; Stearic Acid; Lauramide Dea; Beeswax; Propylene Glycol; Sodium Tetraborate; Sodium Lauryl Sulfate; Diazolidinyl Urea; Methylparaben; Propylparaben; Triethanolamine; Eucalyptus Oil
                   Dosage Form Cream
                   Company Burn Solution Foundations
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Lauric diethanolamide DIG Info Vanilloid receptor 1 (EC50 = 600 nM) [1]
methylparaben DIG Info Carbonic anhydrase VII (Ki = 780 nM) [2]
Stearic acid DIG Info Phosphodiesterase 3A (IC50 = 3.1 uM) [3]
Sodium lauryl sulfate DIG Info Solute carrier SLCO2B1 (Ki = 1.98 uM) [4]
Propylparaben sodium DIG Info Estrogen receptor alpha (EC50 = 38200 nM) [5]
Trolamine DIG Info Choline acetylase (IC50 < 200000 nM) [6]
Eucalyptol DIG Info Serotonin receptor 3A (IC50 = 257039.58 nM) [7]
Propylene glycol DIG Info Albendazole monooxygenase (Inhibition ratio < 20 %) [8]
References
1 Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity. J Med Chem. 2006 Apr 6; 49(7):2333-8.
2 Mono-/dihydroxybenzoic acid esters and phenol pyridinium derivatives as inhibitors of the mammalian carbonic anhydrase isoforms I, II, VII, IX, XII and XIV. Bioorg Med Chem. 2013 Mar 15; 21(6):1564-9.
3 The activities of drug inactive ingredients on biological targets. Science. 2020 Jul 24;369(6502):403-413.
4 Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives. Proc Natl Acad Sci U S A. 2020 Jul 7;117(27):16009-16018.
5 Discovery of natural estrogen receptor modulators with structure-based virtual screening. Bioorg Med Chem Lett. 2013 Jun 1; 23(11):3329-33.
6 Chemistry and biological activities of N,N-dimethylaminoethyl acrylate, a choline acetyltransferase inhibitor. J Med Chem. 1976 Feb; 19(2):300-3.
7 Progress in the discovery of small molecule modulators of the Cys-loop superfamily receptors. Bioorg Med Chem Lett. 2017 Aug 1; 27(15):3207-3218.
8 Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm. 2008 Sep;70(1):279-88.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.